Yang Yang, Chen Lifeng, Zhang Yanjun, Fu Wenqian, Liu Dandan, Jiang Tianyu
Department of Neurology, The 2nd Medical Center of Chinese PLA General Hospital, Beijing, China.
Department of Neurosurgery, The 1st Medical Center of Chinese PLA General Hospital, Beijing, China.
Front Pharmacol. 2025 Jun 24;16:1607443. doi: 10.3389/fphar.2025.1607443. eCollection 2025.
Elderly patients with Type 2 Diabetes Mellitus (T2DM) often experience cognitive dysfunction and gait disorders, which significantly affect their quality of life and daily function. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), known as "wonder drugs for weight loss," have shown potential not only for glycemic control but also for improving cognitive function and gait disturbances. GLP-1RAs may exert their effects through various mechanisms, including promoting neurogenesis and synaptic plasticity in the brain, as well as reducing neuroinflammation, thereby improving cognitive and gait impairments either directly or indirectly. This review aims to explore the role of GLP-1RAs in the treatment of diabetes-related cognitive dysfunction and gait disturbances, as well as their potential mechanisms, providing a theoretical basis for clinical treatment.
老年2型糖尿病（T2DM）患者常出现认知功能障碍和步态障碍，这严重影响他们的生活质量和日常功能。胰高血糖素样肽-1受体激动剂（GLP-1RAs），被誉为“减肥神药”，不仅在血糖控制方面显示出潜力，还能改善认知功能和步态障碍。GLP-1RAs可能通过多种机制发挥作用，包括促进大脑中的神经发生和突触可塑性，以及减轻神经炎症，从而直接或间接地改善认知和步态障碍。本综述旨在探讨GLP-1RAs在治疗糖尿病相关认知功能障碍和步态障碍中的作用及其潜在机制，为临床治疗提供理论依据。
